Zevra Therapeutics price target lowered to $23 from $25 at Canaccord

Canaccord lowered the firm’s price target on Zevra Therapeutics (ZVRA) to $23 from $25 and keeps a Buy rating on the shares. The firm noted they reported results with the key updates that the company had received 90 prescription (Rx) enrollment forms for Miplyffa (arimoclomol) for Niemann-Pick Type C (NPC)as of October 31, of which 30% are approved for reimbursement on an imminent launch of the product.